Company news: Novo Nordisk

Share this article:
Novo Nordisk launched a hemophilia app, dubbed HemaGo, which lets patients and caregivers track treatment, dosing and bleed information while monitoring the disease's impact on life events.  Patients enter information, which is then sent to Novo Nordisk's ‘Changing Possibilities in Hemophilia' website and assembled into easy-to-read reports which to be shared with healthcare providers. HemaGo will be available on both Android and Apple platforms.

An aging and increasingly-affluent population, together with forthcoming Rx-to-OTC switches, stands to boost the $32 billion Chinese OTC market, said consultancy Kline & Co., which said growth in the category is six times stronger than in the US, and noting that China's answer to the FDA is weighing broadening its list of indications that OTC drugs may carry to include chronic conditions like high cholesterol, asthma, osteoporosis, migraine and peptic ulcers.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.